…
Site map
Search
Tags
Идентификация
Remember Me
Log in
Forgot your password?
About BDA
Certificates
History
Archive
Legal acts
Administrative services
Registers
Register of pharmaceutical products
Register of vendors and producers
Useful links
Contacts
For citizens
- Choose menu item -
Warnings
Medicines
Pharmacovigilance
Administrative information
For companies
- Choose category -
Information for companies
- Announcements for companies
- Marketing authorisation of medicinal products
- Medical devices
- Medicinal information
- Linguistic check
- Pharmacovigilance / «Companies»
- Clinical trials
- Ethics Committee
- Ethics Committee for Multicenter Trials
- Control of the medicinal products
- Announcements - Medical devices
- Pharmacopoeia
- Announcements for pharmacovigilance
- EU regulations / «Pharmacovigilance»
- BDA instructions / «Pharmacovigilance»
- E-reporting / «Pharmacovigilance»
- CESP
For medical specialists
- Choose menu item -
Announcements
Medicines
Pharmacovigilance
NCA for blood
ulipristal acetate
ulipristal acetate
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids
EMA starts review of Esmya for uterine fibroids
PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids
PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids
Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk
Important!
COVID-19
Administrative information
Over-the-Counter Drugs (OTC)
List of medicinal products under additional monitoring
EMA: Medicines under additional monitoring
Публични оценъчни доклади
About BDA
Certificates
History
Archive
Legal acts
Administrative services
Registers
Register of pharmaceutical products
Register of vendors and producers
Useful links
Contacts
